Noxopharm Limited is an innovative Australian biotech firm focused on discovering and developing novel treatments for cancer and inflammation, utilizing proprietary technology platforms to enhance mRNA vaccines and address various autoimmune diseases.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – SofraTM (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and ChromaTM (oncology).

Why work with us

Noxopharm's Sofra technology platform is based on a breakthrough discovery regarding the role specific Toll-like receptors play in the immune system, and the company has developed both new drugs and robust IP around this innovation. There is also a first clinical trial for this technology starting in mid-2025.

SOF-SKN is a topical treatment containing a proprietary ultra-short oligonucleotide that blocks Toll-like receptor 7, which is overactivated in autoimmune diseases. It is targeted at the skin disease caused by cutaneous lupus erythematosus (CLE).

SOF-VAC technology reduces the reactogenicity caused by mRNA vaccines at its source. With a well-defined selective mechanism of action, the oligos in the SOF-VAC program can improve vaccine safety while preserving and potentially increasing vaccine efficacy.

There are several licensing opportunities available that can be specifically designed to complement existing research and product portfolios, or support entry into new markets.